OBSOLETE: Aleukemic mast cell leukemia

Aleukemic mast cell leukemia (Orphanet code 158799) is an obsolete diagnostic term that was previously used to describe a variant of mast cell leukemia in which malignant mast cells proliferate in the bone marrow but are not detected in significant numbers in the peripheral blood. Mast cell leukemia itself is an extremely rare and aggressive form of systemic mastocytosis, a group of disorders characterized by the abnormal accumulation of mast cells in various tissues, particularly the bone marrow, skin, liver, spleen, and gastrointestinal tract. In the aleukemic variant, the absence of circulating mast cells in the blood made diagnosis more challenging, as the disease burden was primarily confined to the bone marrow and other organs. This term has been rendered obsolete as classification systems for mast cell neoplasms have evolved. Current WHO classifications categorize mast cell leukemia based on updated criteria without distinguishing a separate aleukemic subtype. Patients with mast cell leukemia may experience symptoms related to organ infiltration and mast cell mediator release, including severe flushing, hypotension, abdominal pain, diarrhea, bone pain, hepatosplenomegaly, and cytopenias due to bone marrow failure. The prognosis for mast cell leukemia remains poor, with limited treatment options that may include cytoreductive chemotherapy, tyrosine kinase inhibitors (such as midostaurin), and in select cases, allogeneic stem cell transplantation. Because this entity is now obsolete, patients and clinicians should refer to the current classification of mast cell leukemia under systemic mastocytosis for up-to-date diagnostic criteria and management guidelines.

Common questions about OBSOLETE: Aleukemic mast cell leukemia